Better Health. Better Life.

mission

Our Mission

M Pharmaceutical is focused on providing drug treatments and biomedical technologies that improve the health and outcomes for people facing the medical issues of obesity & infertility, and intimacy issues.

mission

Our Objective

M Pharmaceutical is committed to developing and commercializing its innovative drug treatments and biomedical technologies which offer the end user realistic solutions based on the principles of reduced invasiveness and enhanced effectiveness.

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.


Biomedical Technology Portfolio

M Pharmaceutical has exclusive rights to Trimeo Weight Loss Capsules, a biomedical technology to manage obesity and diabetes. 

Obesity Management Treatment

Trimeo Weight Loss Capsules are drug free, individually controllable expandable implements that result in a dynamic gastric volume reduction, inducing a feeling of early satiety and reducing food intake. This third generation technology has 3 US and Canadian patents, 3 issued in the EU and 4 pending patents. 

Management & Board of Directors

Gary A. Thompson, B.S., President & CEO M-Pharmaceutical U.S.A. Inc.

  • 30 years plus of sales and management experience in Fortune 500 health care organizations and start up pharmaceutical companies.
  • He has served as Vice President of sales for Cigna Healthcare managing billions of assets over his career.
  • Management and leadership roles with start up ventures including ToConceive LLC., (510K FDA Clearance ) in women's health and wellness, and in the obesity space as President of M-Pharma's newly acquired Chelatexx, LLC., C-103 reformulated orlistat.

Brian Keane, BSc, Interim President and CEO

  • 17 years in capital markets experience
  • Experience with investment funds
  • Experience working in several investment banks

Dr. Christopher Andrews, M.D., MSc, FRCPC, Director

  • Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN
  • Specialist in stomach disorders and physiology, with advanced training in gastrointestinal motility and function
  • Masters Degree in Clinical Health Research from the Mayo Clinic

D. Richard Skeith, BA/JD, Director

  • BA (Hons) in Economics, University of Alberta; JD Faculty of Law, University of Alberta
  • Practicing Lawyer with specialized focus on publicly traded companies
  • Extensive experience as an Officer or Director of multiple public companies in sectors including pharmaceuticals, mining, oil and gas and real estate

Offices in Vancouver, BC and Calgary, AB

Head Office

734, 1055 Dunsmuir St. (P) 604-428-0511
Vancouver, BC., Canada (F) 604-428-0512
V7X 1B1 (E) email

Investor Relations: 604-428-0511

Check1

Check2

Check3